Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PF-06459988

Known as: Mutant-selective EGFR Inhibitor PF-06459988 
An orally available, small molecule, third-generation, irreversible inhibitor of epidermal growth factor receptor (EGFR) mutant (EGFRm) forms with… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Mutant epidermal growth factor receptor (EGFR) is a major driver of non-small-cell lung cancer (NSCLC). Marketed first generation… Expand
2016
2016
First generation EGFR TKIs (gefitinib, erlotinib) provide significant clinical benefit for NSCLC cancer patients with oncogenic… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5